BlackRock Joins Goldfinch Bio's $100M Series B Round

Law360 (June 30, 2020, 4:28 PM EDT) -- Kidney disease-focused biotechnology company Goldfinch Bio Inc. has raised $100 million in a financing round led by Eventide Asset Management and attracting new investors including funds managed by BlackRock Investment LLC, in a deal worked on by Ropes & Gray LLP, the company said Tuesday.

Cambridge, Massachusetts-based Goldfinch Bio said that the money from the Series B financing will fund the development and clinical trials for two of its drug treatments. An Eventide analyst will also join Goldfinch's board of directors, the biotech said.

Other new investors that contributed to the round included Wellington Management Co., Ally Bridge Group, Casdin Capital...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!